Advancement in chiral heterocycles for the antidiabetic activity

Chirality. 2024 Feb;36(2):e23637. doi: 10.1002/chir.23637.

Abstract

For the synthesis and development of pharmaceuticals, chirality is an important structural component. Chiral heterocyclic compounds have annoyed the interest of synthetic chemists who are working to create useful and efficient techniques for these molecules. As indicated by the expanding number of chiral drugs created in the last two decades, the link between chirality and pharmacological activity has become more important in the pharmaceutical and biopharmaceutical industries. Approximately 65% of currently used drugs are chiral, and many of them are promoted as racemates in many circumstances. There are a growing number of new chiral heterocyclic compounds with important biological properties and intriguing uses in medical chemistry and drug discovery. In this study, we review current breakthroughs in chiral heterocycles and their different physiological activities that have been published in the last year (from 2010 to early 2023). This study focuses on the current trends in the use of chiral heterocycles in drug design and the creation of several powerful and competent candidates for diabetic illnesses.

Keywords: biological activity; chirality; configuration; heterocyclic; stereo-specificity.

Publication types

  • Review

MeSH terms

  • Drug Design
  • Drug Discovery
  • Heterocyclic Compounds* / chemistry
  • Heterocyclic Compounds* / pharmacology
  • Hypoglycemic Agents*
  • Stereoisomerism

Substances

  • Hypoglycemic Agents
  • Heterocyclic Compounds

Grants and funding